Ginkgo Bioworks Holdings (DNA) Share-based Compensation (2020 - 2026)

Ginkgo Bioworks Holdings' Share-based Compensation history runs 7 years deep, the most recent figure standing at $15.9 million for Q1 2026.

• Quarterly Share-based Compensation fell 8.82% year-over-year to $15.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $77.5 million (up 449.8% YoY) and the FY2025 annual result came in at $81.5 million, changed N/A from the prior year.
• Share-based Compensation was $15.9 million for Q1 2026 at Ginkgo Bioworks Holdings, down from $21.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $652.8 million in Q1 2022 and bottomed at -$187.0 million in Q4 2023.
• A 5-year average of $119.4 million and a median of $38.2 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation soared 553138.14% — and 2023, when it sank 272.9%.
• Ginkgo Bioworks Holdings' Share-based Compensation stood at $108.2 million in 2022, then sank by 272.9% to -$187.0 million in 2023, then jumped by 50.92% to -$91.8 million in 2024, then surged by 122.91% to $21.0 million in 2025, then decreased by 24.61% to $15.9 million in 2026.
• Business Quant data shows DNA's Share-based Compensation at $15.9 million in Q1 2026, $21.0 million in Q4 2025, and $18.1 million in Q3 2025.